Focused On-demand Library for Small ribosomal subunit protein eS28

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P62857

UPID:

RS28_HUMAN

Alternative names:

40S ribosomal protein S28

Alternative UPACC:

P62857; P25112

Background:

Small ribosomal subunit protein eS28, also known as 40S ribosomal protein S28, plays a crucial role in protein synthesis. It is a component of the small ribosomal subunit, essential for the synthesis of proteins within the cell. This protein is involved in the assembly of the SSU processome in the nucleolus, facilitating RNA folding, modifications, rearrangements, and cleavage, crucial for ribosome biogenesis.

Therapeutic significance:

Small ribosomal subunit protein eS28 is linked to Diamond-Blackfan anemia 15, with mandibulofacial dysostosis, a condition characterized by congenital non-regenerative hypoplastic anemia. Understanding the role of Small ribosomal subunit protein eS28 could open doors to potential therapeutic strategies for this and related disorders.